

Feline Vaccination Recommendations¹

	Basic vaccination			_	
Lifestyle	Primary vaccii	nation course*** 3-4 weeks later	First annual booster 1 year after completion of the primary course	Boosters after 1-year booster	
Strictly indoor cats No outdoor access, and no contact with outdoor cats.	RCP	RCP	RCP	RCP: 3-year booster	
Outdoor and indoor/outdoor cats Cats with outdoor access or contact with outdoor cats.	RCP FeLV	RCP FeLV	RCP FeLV	RC FeLV: 1-year booster P: 3-year booster	
Shelter cats	RCPCh FeLV	RCPCh FeLV	RCPCh FeLV	RC(Ch)** FeLV: 1-year booster P: 3-year booster	
Breeding catteries	RCPCh (FeLV)*	RCPCh (FeLV)*	RCPCh (FeLV)*	RC(Ch)**: 1-year booster P: 3-year booster (FeLV)*: 1-year booster	

^{*} FeLV vaccination is recommended in breeding catteries if there is outdoor access in a high-risk geographical area

The PUREVAX® range contains a combination of the following active ingredients: attenuated feline rhinotracheitis herpesvirus (FHV F2 strain), inactivated feline calicivirus antigens (FCV 431 and G1 strains), attenuated Chlamydophila felis (905 strain), attenuated feline panleucopenia virus (VCP51). PUREVAX® RAbies contains Rabies recombinant canarypox virus (VCP65). PUREVAX® FelV is indicated for active immunisation of cats of 8 weeks of aginst feline viral rhinotracheitis to reduce clinical signs; and against feline viral rhinotracheitis to reduce clinical signs; and against feline viral rhinotracheitis to reduce clinical signs; and against feline panleucopenia to prevent mortality and clinical signs. PUREVAX® RCP FelV is indicated for active immunisation of cats aged 8 weeks and older: against feline viral rhinotracheitis to reduce clinical signs; against calicivirus infection to reduce clinical signs; and against feline panleucopenia to prevent mortality and clinical signs; and against leukaemia to prevent persistent viraemia and clinical signs of the related disease. PUREVAX® RCPCh is indicated for active immunisation of cats aged 8 weeks and older: against feline viral rhinotracheitis to reduce clinical signs; against feline panleucopenia to prevent mortality and clinical signs; against feline viral rhinotracheitis to reduce clinical signs, against feline panleucopenia to prevent mortality and clinical signs, against feline viral rhinotracheitis to reduce clinical signs, against feline viral rhinotracheitis to reduce clinical signs, against feline viral rhinotracheitis to reduce clinical signs; against feline viral rhinotracheitis to reduce clinical signs; against feline viral rhinotracheitis to reduce clinical signs, purple viral rhinotracheitis to reduce clinical signs, purple viral rhinotracheitis to reduce clinical s



^{**} To protect against Chlamydophila felis, give RCPCh annually

^{***} In certain high risk situations primary course vaccine variations may be suggested. For further information please see 2015 ABCD recommendations for indoor/outdoor cats, rescue shelter cats and breeding catteries.

^{1.} Hosie, Margaret J et al. "Matrix vaccination guidelines: 2015 ABCD recommendations for indoor/outdoor cats, rescue shelter cats and breeding catteries." Journal of feline medicine and surgery vol. 17,7 (2015): 583-7. doi:10.1177/1098612X15590732






A BROAD and flexible range, now available in 0.5 ml

Providing combinations you will need, offering flexibility and convenience

THE PUREVAX RANGE



FULLY FLEXIBLE RANGE



COMBINATION PACKS



